The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.
 
Yvonne Marie Mowery
Employment - Duke Health Private Diagnostic Clinic
Honoraria - Oakstone; UpToDate
Research Funding - Merck (Inst)
 
Donna Niedzwiecki
No Relationships to Disclose
 
Jennifer Hsing Choe
Employment - Private Diagnostic Clinic
Research Funding - Merck (Inst)
 
David G. Kirsch
Stock and Other Ownership Interests - Lumicell; X-RAD Therapeutics
Consulting or Advisory Role - Lumicell
Research Funding - Amgen; Bristol-Myers Squibb; Calithera Biosciences; Merck; Varian Medical Systems; X-RAD Therapeutics
Patents, Royalties, Other Intellectual Property - Patent on an imaging device licensed to Lumicell; Patent on small molecule radiosensitizers by XRAD Therapeutics; Royalty on an imaging agent being commercialized by Lumicell
 
David M. Brizel
Employment - Private Diagnostic Clinic
Honoraria - UpToDate